Tailoring epilepsy meds for kids: a dosing breakthrough in sight?

NCT ID NCT03196466

Completed Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 753 children with epilepsy to better understand how their bodies process antiepileptic drugs. Researchers measured drug levels in the blood and considered factors like age, weight, and other medications. The goal is to create models that help doctors choose the right dose for each child, improving safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: antiepileptic drugs (valproic acid, carbamazepine, phenobarbital, and others)
What this could lead to: If successful, this could help doctors give more personalized, safer doses of epilepsy drugs to children, reducing side effects and improving seizure control.
What could go wrong: This is an observational modeling study, not a treatment trial. It may not lead to immediate changes in clinical practice, and the models need further validation before widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY

Contacts and locations

Locations

AP-HP Cochin

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.